National Heart and Lung Institute, Imperial College London, London, UK.
Centre de Recherche cardio-thoracique de Bordeaux, Univ-Bordeaux, Pessac, France.
Respirology. 2021 May;26(5):419-441. doi: 10.1111/resp.14032. Epub 2021 Mar 9.
An individual's experience of COPD is determined by many factors in addition to the pathological features of chronic bronchitis and emphysema and the symptoms that derive directly from them. Multimorbidity is the norm rather than the exception, so most people with COPD are living with a range of other medical problems which can decrease overall quality of life. COPD is caused by the inhalation of noxious particles or gases, in particular tobacco smoke, but also by early life disadvantage impairing lung development and by occupations where inhaled exposures are common (e.g. industrial, farming and cleaning work). Wealthy people are therefore relatively protected from developing COPD and people who do develop the condition may have reduced resources to cope. COPD is also no longer a condition that predominantly affects men. The prevalence of COPD among women has equalled that of men since 2008 in many high-income countries, due to increased exposure to tobacco, and in low-income countries due to biomass fuels. COPD is one of the leading causes of death in women in the USA, and death rates attributed to COPD in women in some countries are predicted to overtake those of men in the next decade. Many factors contribute to this phenomenon, but in addition to socioeconomic and occupational factors, there is increasing evidence of a higher susceptibility of females to smoking and pollutants. Quality of life is also more significantly impaired in women. Although most medications (bronchodilators and inhaled corticosteroids) used to treat COPD demonstrate similar trends for exacerbation prevention and lung function improvement in men and women, this is an understudied area and clinical trials frequently have a preponderance of males. A better understanding of gender-based predictors of efficacy of all therapeutic interventions is crucial for comprehensive patient care. There is an urgent need to recognize the increasing burden of COPD in women and to facilitate global improvements in disease prevention and management in this specific population. Many individuals with COPD follow a trajectory of both lung function decline and also multimorbidity. Unfavourable lung function trajectories throughout life have implications for later development of other chronic diseases. An enhanced understanding of the temporal associations underlying the development of coexisting diseases is a crucial first step in unravelling potential common disease pathways. Lessons can be learned from exploring disease trajectories of other NCD as well as multimorbidity development. Further research will be essential to explain how early life risk factors commonly influence trajectories of COPD and other diseases, how different diseases develop in relation to each other in a temporal way and how this ultimately leads to different multimorbidity patterns in COPD. This review integrates new knowledge and ideas pertaining to three broad themes (i) the overall burden of disease in COPD, (ii) an unappreciated high burden in women and (iii) the contrast of COPD trajectories and different multimorbidity patterns with trajectories of other NCD. The underlying pathology of COPD is largely irreversible, but many factors noted in the review are potentially amenable to intervention. Health and social care systems need to ensure that effective treatment is accessible to all people with the condition. Preventive strategies and treatments that alter the course of disease are crucial, particularly for patients with COPD as one of many problems.
个体的 COPD 体验除了慢性支气管炎和肺气肿的病理特征以及直接由此产生的症状外,还受到许多因素的影响。多病共存是常态,而非例外,因此大多数 COPD 患者都患有一系列其他医疗问题,这会降低整体生活质量。COPD 是由吸入有害颗粒或气体引起的,特别是烟草烟雾,但也与早期生活劣势损害肺发育以及吸入暴露常见的职业有关(例如工业、农业和清洁工作)。因此,富人相对不易患上 COPD,而患上这种疾病的人可能资源有限。COPD 也不再是主要影响男性的疾病。在许多高收入国家,由于女性接触烟草的增加,以及在低收入国家由于生物量燃料的使用,自 2008 年以来,女性 COPD 的患病率已与男性持平。在美国,COPD 是女性死亡的主要原因之一,在一些国家,女性归因于 COPD 的死亡率预计在未来十年内超过男性。许多因素促成了这一现象,但除了社会经济和职业因素外,越来越多的证据表明女性对吸烟和污染物的敏感性更高。女性的生活质量也受到更大的影响。尽管大多数用于治疗 COPD 的药物(支气管扩张剂和吸入性皮质类固醇)在预防男性和女性的恶化和改善肺功能方面都显示出相似的趋势,但这是一个研究不足的领域,临床试验通常以男性为主。更好地了解所有治疗干预措施的基于性别的疗效预测因素对于全面的患者护理至关重要。迫切需要认识到女性 COPD 的负担不断增加,并促进在这一特定人群中改善疾病预防和管理。许多 COPD 患者都经历了肺功能下降和多病共存的轨迹。一生中不利的肺功能轨迹对以后发生其他慢性疾病有影响。深入了解共存疾病发展背后的时间关联是揭示潜在共同疾病途径的关键第一步。从探索其他非传染性疾病的疾病轨迹和多病共存发展中可以吸取经验教训。进一步的研究对于解释早期生活风险因素如何共同影响 COPD 和其他疾病的轨迹、不同疾病如何在时间上相互发展以及最终导致 COPD 中不同的多病共存模式至关重要。本综述整合了与三个广泛主题相关的新知识和新想法:(i)COPD 的总体疾病负担,(ii)女性未被认识到的高负担,以及(iii)COPD 轨迹和不同的多病共存模式与其他非传染性疾病的轨迹之间的对比。COPD 的潜在病理学在很大程度上是不可逆转的,但综述中提到的许多因素都可能通过干预来改变。卫生和社会保健系统需要确保所有患有该疾病的人都能获得有效的治疗。预防策略和改变疾病进程的治疗方法至关重要,对于 COPD 患者尤其如此,因为 COPD 是众多问题之一。